Grundläggande statistik
| CIK | 810084 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bioject Medical Technologies Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| November 27, 2015 |
Bioject Medical Technologies FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Rep |
|
| November 27, 2015 |
BIOJECT REPORTS UNAUDITED THIRD QUARTER 2015 FINANCIAL RESULTS EX-99.1 2 d33599dex991.htm EX-99.1 EXHIBIT 99.1 BIOJECT REPORTS UNAUDITED THIRD QUARTER 2015 FINANCIAL RESULTS Tigard, OR – November 27, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the third quarter ended September 30, 2015. The financial results are unaudited and ac |
|
| November 27, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d33599d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2015 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-10996 |
|
| August 14, 2015 |
BIOJECT REPORTS UNAUDITED SECOND QUARTER 2015 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Tony Chow President and Chief Executive Officer/Chief Financial Officer 503-632-8001 ext. 4132 BIOJECT REPORTS UNAUDITED SECOND QUARTER 2015 FINANCIAL RESULTS Tigard, OR ? August 14, 2015 ? Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, |
|
| August 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2015 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other jur |
|
| August 14, 2015 |
Bioject Medical Technologies NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report o |
|
| May 15, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other jurisdictio |
|
| May 15, 2015 |
Bioject Medical Technologies NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report |
|
| May 15, 2015 |
BIOJECT REPORTS UNAUDITED FIRST QUARTER 2015 FINANCIAL RESULTS EX-99.1 EXHIBIT 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Tony Chow President and CEO/Chief Financial Officer 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED FIRST QUARTER 2015 FINANCIAL RESULTS Tigard, OR ? May 15, 2015 ? Bioject Medical Technologies Inc. (OTC Pink: BJCT), an innovative developer and manufacturer of needle-free injection therapy systems, today repor |
|
| April 1, 2015 |
EX-10.2 EXHIBIT 10.2 SECURITY AGREEMENT This Security Agreement (this Agreement) is made March 3, 2015 by and among Bioject Medical Technologies Inc. (the Company) and its wholly owned subsidiary Bioject Inc. (the Subsidiary), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the Grantors), and Mark A. Logomasini & Associates |
|
| April 1, 2015 |
SENIOR SECURED BRIDGE PROMISSORY NOTE EX-10.4 EXHIBIT 10.4 SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, O |
|
| April 1, 2015 |
SENIOR SECURED BRIDGE PROMISSORY NOTE EX-10.5 EXHIBIT 10.5 SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, O |
|
| April 1, 2015 |
SENIOR SECURED BRIDGE PROMISSORY NOTE EX-10.1 EXHIBIT 10.1 SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ACT) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, O |
|
| April 1, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other juris |
|
| April 1, 2015 |
SENIOR SECURED PROMISSORY NOTE EX-10.6 EXHIBIT 10.6 SENIOR SECURED PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER UNITED STATES FEDERAL OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED OR ASSIGNED FOR VALUE, DIRECTLY OR INDIRECTLY, NOR MAY THE SECURITIES BE TRANSFERRED ON THE BOOKS OF THE CORPORATION, WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLI |
|
| April 1, 2015 |
SENIOR SECURED PROMISSORY NOTE EX-10.7 EXHIBIT 10.7 SENIOR SECURED PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER UNITED STATES FEDERAL OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED OR ASSIGNED FOR VALUE, DIRECTLY OR INDIRECTLY, NOR MAY THE SECURITIES BE TRANSFERRED ON THE BOOKS OF THE CORPORATION, WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLI |
|
| April 1, 2015 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT EX-10.8 EXHIBIT 10.8 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this ?IP Agreement?) is made February 18, 2015 by and among Bioject Medical Technologies Inc. (?Bioject?) and its wholly owned subsidiary Bioject Inc. (the ?Subsidiary?), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the ? |
|
| April 1, 2015 |
EX-10.3 EXHIBIT 10.3 SENIOR BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, OR AN OPI |
|
| April 1, 2015 |
BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2014 FINANCIAL RESULTS EX-99.1 EXHIBIT 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Tony Chow President and CEO/Chief Financial Officer 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2014 FINANCIAL RESULTS Tigard, OR March 25, 2015 Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today r |
|
| March 30, 2015 |
Bioject Medical Technologies NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One) x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Repor |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* BIOJECT MEDICAL TECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09059T206 (CUSIP Number) James C. Gale 152 W. 57th Street, 19th Floor, New York, New York 10019 212-419-3906 (Name, Address and Telephone Number of Person Auth |
|
| November 12, 2014 |
BIOJECT REPORTS UNAUDITED THIRD QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Mark Logomasini President and CEO 503-692-8001 ext. 4121 Tony K. Chow Chief Financial Officer 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED THIRD QUARTER 2014 FINANCIAL RESULTS Tigard, OR – November 12, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free inj |
|
| November 12, 2014 |
BJCT / Bioject Medical Technologies Inc. NT 10-Q - - NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One) ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transit |
|
| November 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other jurisd |
|
| August 15, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other juris |
|
| August 15, 2014 |
BIOJECT REPORTS UNAUDITED SECOND QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Mark Logomasini President and CEO 503-692-8001 ext. 4121 Tony K. Chow Chief Financial Officer 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED SECOND QUARTER 2014 FINANCIAL RESULTS Tigard, OR – August 15, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free inje |
|
| August 15, 2014 |
EX-10.3 Exhibit 10.3 SECURITY AGREEMENT This Security Agreement (this “Agreement”) is made June 25, 2014 by and among Bioject Medical Technologies Inc.(the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the “Grantors”), and Mark A. Logomasini & Associates, |
|
| August 15, 2014 |
SENIOR SECURED BRIDGE PROMISSORY NOTE EX-10.2 Exhibit 10.2 SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, O |
|
| August 15, 2014 |
BJCT / Bioject Medical Technologies Inc. NT 10-Q - - NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition |
|
| August 15, 2014 |
SENIOR SECURED BRIDGE PROMISSORY NOTE EX-10.1 Exhibit 10.1 SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, O |
|
| July 31, 2014 |
BJCT / Bioject Medical Technologies Inc. / FLYNN EDWARD L - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BIOJECT MEDICAL TECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09059T206 (CUSIP Number) Edward Flynn 7180 SW Sandburg Street, Suite 100 Tigard, Oregon 97223 503-692-8001 (Name, Address and Telephone Number of Person Authorized to Rece |
|
| July 3, 2014 |
BJCT / Bioject Medical Technologies Inc. / Logomasini Mark - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BIOJECT MEDICAL TECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09059T206 (CUSIP Number) Mark A. Logomasini 26212 Dimension Drive, Suite 260 Lake Forest, California 92630 (949) 215-2755 (Name, Address and Telephone Number of Person Aut |
|
| July 3, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other jurisd |
|
| July 3, 2014 |
CHOW EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 CHOW EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is dated July 1, 2014 (the “Effective Date”) between: BIOJECT MEDICAL TECHNOLOGIES INC. (“BMT”), a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 and business office at 26212 Dimension Dri |
|
| June 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* BIOJECT MEDICAL TECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09059T206 (CUSIP Number) John T. Unger 333 Clay Street, Suite 3300, Houston, Texas 77002 713-653-8811 (Name, Address and Telephone Number of Person Authorized |
|
| May 16, 2014 |
Form NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Trans |
|
| May 15, 2014 |
BIOJECT REPORTS UNAUDITED FIRST QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Mark Logomasini President and CEO 503-692-8001 ext. 4121 Christine Farrell Vice President of Finance 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED FIRST QUARTER 2014 FINANCIAL RESULTS Tigard, OR – May 15, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), an innovative developer and manufacturer of n |
|
| May 15, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 000-15360 Oregon 93-1099680 (State or other juri |
|
| May 6, 2014 |
FORM OF SENIOR SECURED PROMISSORY NOTE EX-10.2 Exhibit 10.2 FORM OF SENIOR SECURED PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER UNITED STATES FEDERAL OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED OR ASSIGNED FOR VALUE, DIRECTLY OR INDIRECTLY, NOR MAY THE SECURITIES BE TRANSFERRED ON THE BOOKS OF THE CORPORATION, WITHOUT REGISTRATION OF SUCH SECURITIES UNDER A |
|
| May 6, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other juri |
|
| May 6, 2014 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT EX-10.4 Exhibit 10.4 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this “IP Agreement”) is made April 30, 2014 by and among Bioject Medical Technologies Inc. (“Bioject”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the “Gra |
|
| May 6, 2014 |
ARTICLES OF AMENDMENT TO 2002 RESTATED ARTICLES OF INCORPORATION BIOJECT MEDICAL TECHNOLOGIES INC. EX-10.5 Exhibit 10.5 ARTICLES OF AMENDMENT TO 2002 RESTATED ARTICLES OF INCORPORATION OF BIOJECT MEDICAL TECHNOLOGIES INC. 1. The name of the corporation (the “Corporation”) is Bioject Medical Technologies Inc. 2. The 2002 Restated Articles of Incorporation of the Corporation are amended to add a new Section 9 to Article IV at the end of Article IV to read in its entirety as follows: “Section 9. A |
|
| May 6, 2014 |
EX-10.3 Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of the 30th day of April, 2014 (the “Effective Date”) between Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), and the parties set forth on the signature page and Exhibit A hereto (each, an “Investor” and collectively, the “Investors”). RECITA |
|
| May 6, 2014 |
BIOJECT MEDICAL TECHNOLOGIES INC RESTRUCTURING AGREEMENT EX-10.1 Exhibit 10.1 BIOJECT MEDICAL TECHNOLOGIES INC RESTRUCTURING AGREEMENT This Restructuring Agreement (the “Agreement”), dated as of April 30, 2014, is by and among of Bioject Medical Technologies Inc. (“Bioject’) and the holders of its preferred stock and debt who are parties hereto (the “Holders”). Whereas on March 18, 2014 the Board of Directors of Bioject approved a plan to restructure it |
|
| March 31, 2014 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One) x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transiti |
|
| March 20, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2014 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other juri |
|
| March 20, 2014 |
BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2013 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Mark Logomasini President and CEO 503-692-8001 ext. 4121 Christine Farrell Vice President of Finance 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2013 FINANCIAL RESULTS Tigard, OR – March 13, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer |
|
| March 20, 2014 |
BIOJECT SEEKING TO RESTRUCTURE ITS BALANCE SHEET EX-99.2 Exhibit 99.2 For Further Information Contact: Bioject Medical Technologies Inc. Mark Logomasini President and CEO 503-692-8001 ext. 4121 Christine Farrell Vice President of Finance 503-692-8001 ext. 4132 BIOJECT SEEKING TO RESTRUCTURE ITS BALANCE SHEET Tigard, OR – March 20, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection the |
|
| November 14, 2013 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transi |
|
| October 1, 2013 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT EX-10.2 EXHIBIT 10.2 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this “IP Agreement”) is made September 25, 2013 by and among Bioject Medical Technologies Inc.(the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, t |
|
| October 1, 2013 |
SENIOR SECURED PROMISSORY NOTE EX-10.1 EXHIBIT 10.1 SENIOR SECURED PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, OR AN OP |
|
| October 1, 2013 |
EX-10.3 EXHIBIT 10.3 Amendments to Senior Secured Bridge Promissory Notes and related security agreements dated September 25, 2013 by and among Bioject Medical Technologies Inc. (the “Corporation”), Bioject Inc. (the “Subsidiary”), the Purchasers and the Purchaser (as defined below). Edward Flynn, Albert Hansen, Mark Logomasini and Richard Richieri (together, the “Purchasers”), the holders of the |
|
| October 1, 2013 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2013 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other juris |
|
| August 30, 2013 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2013 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other jurisdic |
|
| August 30, 2013 |
SENIOR SECURED BRIDGE PROMISSORY NOTE Exhibit 10.1 SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, OR AN OPI |
|
| August 30, 2013 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT EX-10.2 Exhibit 10.2 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this “IP Agreement”) is made August 28, 2013 by and among Bioject Medical Technologies Inc. (the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the |
|
| August 15, 2013 |
FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transit |
|
| July 17, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2013 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-15360 Oregon 93-1099680 (State or other juris |
|
| July 17, 2013 |
FORM OF SENIOR SECURED BRIDGE PROMISSORY NOTE EX-10.1 2 d570207dex101.htm EX-10.1 Exhibit 10.1 FORM OF SENIOR SECURED BRIDGE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY |
|
| July 17, 2013 |
FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Exhibit 10.2 FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this “IP Agreement”) is made July 16, 2013 by and among Bioject Medical Technologies Inc.(the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the “G |
|
| May 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report |
|
| April 9, 2013 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-15360 CUSIP Number: 09059T206 (Check One) x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transiti |
|
| February 20, 2013 |
LOGOMASINI EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 LOGOMASINI EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is dated February 15, 2013 (the “Effective Date”) between: BIOJECT MEDICAL TECHNOLOGIES INC. (“BMT”), a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 BIOJECT INC. (“Bioject,” and to |
|
| February 20, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2013 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 000-15360 Oregon 93-1099680 (State or other |
|
| February 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* BIOJECT MEDICAL TECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09059T206 (CUSIP Number) John T. Unger 600 Travis, Suite 5800, Houston, Texas 77002 713-993-4645 (Name, Address and Telephone Number of Person Authorized to Re |
|
| February 12, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2013 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 000-15360 Oregon 93-1099680 (State or other |
|
| February 12, 2013 |
BIOJECT REPORTS UNAUDITED YEAR-END AND QUARTERLY 2012 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Further Information Contact: Bioject Medical Technologies Inc. Mark Logomasini President and CEO 503-692-8001 ext. 4121 Christine Farrell Vice President of Finance 503-692-8001 ext. 4132 BIOJECT REPORTS UNAUDITED YEAR-END AND QUARTERLY 2012 FINANCIAL RESULTS Tigard, OR – February 11, 2013 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of |
|
| January 30, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2013 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 000-15360 Oregon 93-1099680 (State or other |
|
| January 30, 2013 |
ARTICLES OF AMENDMENT TO 2002 RESTATED ARTICLES OF INCORPORATION BIOJECT MEDICAL TECHNOLOGIES INC. Articles of Amendment to 2002 Restated Articles of Incorporation Exhibit 3.1 ARTICLES OF AMENDMENT TO 2002 RESTATED ARTICLES OF INCORPORATION OF BIOJECT MEDICAL TECHNOLOGIES INC. 1. The name of the corporation (the “Corporation”) is Bioject Medical Technologies Inc. 2. The 2002 Restated Articles of Incorporation of the Corporation are amended to add a new Section 8 to Article IV at the end of Arti |
|
| January 30, 2013 |
BIOJECT MEDICAL TECHNOLOGIES INC. SERIES H CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT Series H Convertible Preferred Stock Purchase Agreement Exhibit 10.1 BIOJECT MEDICAL TECHNOLOGIES INC. SERIES H CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT This Purchase Agreement (this “Agreement”) is made and entered into as of January 24, 2013, by and among Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), and the investors whose names and addresses are set forth on t |
|
| January 30, 2013 |
Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of the 24th day of January, 2013 (the “Effective Date”) between Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), and the parties set forth on the signature page and Exhibit A hereto (each, an “Investor” and collectively, |
|
| November 15, 2012 |
Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2012 |
Notification Of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 1, 2012 |
RW BIOJECT, INC. 7180 S.W. Sandburg St., Suite 100 Tigard, OR 97223 TELEPHONE: (503) 692-8001 FAX: (503) 692-6698 WWW.BIOJECT.COM June 1, 2012 VIA EDGAR Securities and Exchange Commission Division of Corporate and Finance 100 F Street NE Washington, DC 20549-7010 Re: Bioject Medical Technologies Inc. (the “Company”) Request to Withdraw Registration Statement on Form S-1 (RW) SEC File Number 333-17 |
|
| May 16, 2012 |
Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 4, 2012 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2012 BIOJECT MEDICAL TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Commission File Number: 000-15360 Oregon 93-1099680 (State or other ju |
|
| April 4, 2012 |
Letter re Change in Certifying Accountant Exhibit 16 April 3, 2012 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6561 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 3, 2012 of Bioject Medical Technologies, Inc. and are in agreement with the statements contained therein. Respectfully, /s/ Moss Adams LLP |
|
| April 2, 2012 |
Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
